Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

CRISPR01:59

CRISPR

49.7K
Genome editing technologies allow scientists to modify an organism’s DNA via the addition, removal, or rearrangement of genetic material at specific genomic locations. These types of techniques could potentially be used to cure genetic disorders such as hemophilia and sickle cell anemia. One popular and widely used DNA-editing research tool that could lead to safe and effective cures for genetic disorders is the CRISPR-Cas9 system. CRISPR-Cas9 stands for Clustered Regularly Interspaced...
49.7K
Homologous Recombination02:31

Homologous Recombination

50.2K
The basic reaction of homologous recombination (HR) involves two chromatids that contain DNA sequences sharing a significant stretch of identity. One of these sequences uses a strand from another as a template to synthesize DNA in an enzyme-catalyzed reaction. The final product is a novel amalgamation of the two substrates. To ensure an accurate recombination of sequences, HR is restricted to the S and G2 phases of the cell cycle. At these stages, the DNA has been replicated already and the...
50.2K
CRISPR and crRNAs02:53

CRISPR and crRNAs

16.8K
Bacteria and archaea are susceptible to viral infections just like eukaryotes; therefore, they have developed a unique adaptive immune system to protect themselves. Clustered regularly interspaced short palindromic repeats and CRISPR-associated proteins (CRISPR-Cas) are present in more than 45% of known bacteria and 90% of known archaea.
The CRISPR-Cas system stores a copy of foreign DNA in the host genome and uses it to identify the foreign DNA upon reinfection. CRISPR-Cas has three different...
16.8K
Gene Therapy00:59

Gene Therapy

25.3K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
25.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sustained clinical remission and relapse of severe eosinophilic asthma following long-term mepolizumab treatment.

Allergology international : official journal of the Japanese Society of Allergology·2026
Same author

Clinical, biological and cytometric characteristics of two patients with a homozygous A91V<i>PRF1</i> mutation.

Clinical & translational immunology·2026
Same author

Occupational category, job type, and sarcoidosis: Findings from a French multicenter study.

Pulmonology·2026
Same author

The IL-10/IL-6 Ratio and the Risk Score: Two Cytokines-Based Predictors for Malignancy-Associated Hemophagocytic Lymphohistiocytosis in Adults (M-HLHa).

American journal of hematology·2026
Same author

Lonvoguran Ziclumeran - In Vivo CRISPR Gene Editing in Hereditary Angioedema.

The New England journal of medicine·2026
Same author

Intensive care admissions for severe immune-related adverse events associated with immune checkpoint inhibitor therapy: a 10-year cohort study.

Journal of critical care·2026

Related Experiment Video

Updated: Jun 9, 2025

CRISPR/Cas9-mediated Targeted Integration In Vivo Using a Homology-mediated End Joining-based Strategy
08:22

CRISPR/Cas9-mediated Targeted Integration In Vivo Using a Homology-mediated End Joining-based Strategy

Published on: March 12, 2018

14.8K

CRISPR-Based Therapy for Hereditary Angioedema.

Danny M Cohn1, Padmalal Gurugama1, Markus Magerl1

  • 1From Amsterdam Cardiovascular Sciences, Amsterdam University Medical Center, University of Amsterdam, Amsterdam (D.M.C., R.S.P); Cambridge University Hospitals, NHS Foundation Trust, Cambridge, United Kingdom (P.G.); the Institute of Allergology, Charité-Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, and Immunology and Allergology, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Berlin (M.M.), and the Department of Children and Adolescents, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt (E.A.-P.) - all in Germany; the Department of Medicine, Campbelltown Hospital and Western Sydney University, Sydney (C.H.K.); University of Lille, U1286-INFINITE-Institute for Translational Research in Inflammation, F-59000, INSERM, and the Department of Internal Medicine and Clinical Immunology, CHU Lille, National Reference Center for Angioedema (CREAK), Lille (D.L.), and CREAK, Angioedema Center of Reference and Excellence (ACARE), Grenoble Alpes University Hospital, and the Translational Research in Autoimmunity and Inflammation Arm (T-RAIG), French National Center for Scientific Research (CNRS), Grenoble (L.B.) - all in France; Intellia Therapeutics, Cambridge, MA (D.M., J.S.B., M.Y.S., A.G., Y.X., A.M.A., D.L.); and the Department of Immunology, Auckland City Hospital, and the Department of Medicine, University of Auckland - both in Auckland, New Zealand (K.L., H.J.L.).

The New England Journal of Medicine
|October 24, 2024
PubMed
Summary
This summary is machine-generated.

A single dose of NTLA-2002 gene therapy significantly reduced hereditary angioedema attacks. This CRISPR-based treatment targeting KLKB1 shows promise for lifelong control of swelling attacks.

More Related Videos

Adeno-Associated Virus-Mediated Delivery of CRISPR for Cardiac Gene Editing in Mice
09:00

Adeno-Associated Virus-Mediated Delivery of CRISPR for Cardiac Gene Editing in Mice

Published on: August 2, 2018

8.1K
Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T Cells
07:56

Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T Cells

Published on: July 22, 2019

11.2K

Related Experiment Videos

Last Updated: Jun 9, 2025

CRISPR/Cas9-mediated Targeted Integration In Vivo Using a Homology-mediated End Joining-based Strategy
08:22

CRISPR/Cas9-mediated Targeted Integration In Vivo Using a Homology-mediated End Joining-based Strategy

Published on: March 12, 2018

14.8K
Adeno-Associated Virus-Mediated Delivery of CRISPR for Cardiac Gene Editing in Mice
09:00

Adeno-Associated Virus-Mediated Delivery of CRISPR for Cardiac Gene Editing in Mice

Published on: August 2, 2018

8.1K
Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T Cells
07:56

Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T Cells

Published on: July 22, 2019

11.2K

Area of Science:

  • Genetics
  • Pharmacology
  • Immunology

Background:

  • Hereditary angioedema (HAE) is a rare genetic disorder causing severe, unpredictable swelling attacks.
  • NTLA-2002 is a novel CRISPR-based gene-editing therapy designed to target the KLKB1 gene.
  • A single administration of NTLA-2002 aims to provide a lifelong solution for HAE management.

Purpose of the Study:

  • To evaluate the efficacy and safety of NTLA-2002 in adults with hereditary angioedema.
  • To assess the impact of single-dose NTLA-2002 on monthly attack rates and plasma kallikrein levels.
  • To explore patient-reported outcomes as a secondary objective.

Main Methods:

  • A Phase 2, randomized, placebo-controlled trial involving adults with HAE.
  • Participants received a single dose of NTLA-2002 (25 mg or 50 mg) or placebo in a 2:2:1 ratio.
  • The primary endpoint was the monthly attack rate from week 1 to week 16; safety and kallikrein levels were secondary endpoints.

Main Results:

  • NTLA-2002 significantly reduced the mean monthly attack rate by 75-77% compared to placebo.
  • A substantial reduction in plasma kallikrein protein levels was observed (-55% for 25 mg, -86% for 50 mg).
  • 40% (25 mg) and 73% (50 mg) of patients receiving NTLA-2002 were attack-free during the study period.

Conclusions:

  • Single-dose NTLA-2002 effectively reduced angioedema attacks and plasma kallikrein levels in HAE patients.
  • The gene-editing therapy demonstrated robust and sustained efficacy.
  • Results support further investigation in a Phase 3 trial for NTLA-2002 in HAE treatment.